DE69636313D1 - Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen - Google Patents

Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen

Info

Publication number
DE69636313D1
DE69636313D1 DE69636313T DE69636313T DE69636313D1 DE 69636313 D1 DE69636313 D1 DE 69636313D1 DE 69636313 T DE69636313 T DE 69636313T DE 69636313 T DE69636313 T DE 69636313T DE 69636313 D1 DE69636313 D1 DE 69636313D1
Authority
DE
Germany
Prior art keywords
methylthienobenzodiazepines
crystal forms
crystal
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636313T
Other languages
English (en)
Other versions
DE69636313T2 (de
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636313(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of DE69636313D1 publication Critical patent/DE69636313D1/de
Publication of DE69636313T2 publication Critical patent/DE69636313T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
DE69636313T 1995-03-24 1996-03-22 Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen Expired - Lifetime DE69636313T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
US409566 1995-03-24

Publications (2)

Publication Number Publication Date
DE69636313D1 true DE69636313D1 (de) 2006-08-10
DE69636313T2 DE69636313T2 (de) 2007-05-31

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
DE19681286T Withdrawn DE19681286T1 (de) 1995-03-24 1996-03-22 Neue Kristallform von Olanzapin
DE69630324T Expired - Lifetime DE69630324T2 (de) 1995-03-24 1996-03-22 Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen
DE69636313T Expired - Lifetime DE69636313T2 (de) 1995-03-24 1996-03-22 Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE69614426T Expired - Lifetime DE69614426T2 (de) 1995-03-24 1996-03-22 Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE19681286T Withdrawn DE19681286T1 (de) 1995-03-24 1996-03-22 Neue Kristallform von Olanzapin
DE69630324T Expired - Lifetime DE69630324T2 (de) 1995-03-24 1996-03-22 Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69614426T Expired - Lifetime DE69614426T2 (de) 1995-03-24 1996-03-22 Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung

Country Status (49)

Country Link
US (1) US5736541A (de)
EP (3) EP0733635B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR002719A1 (de)
AT (4) ATE251627T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE19681286T1 (de)
DK (4) DK1095941T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2159346T3 (de)
FI (1) FI973750A0 (de)
GB (1) GB2313835B (de)
HK (1) HK1013988A1 (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT733635E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205D0 (de)
SI (4) SI0733635T1 (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW513432B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962342B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US6274636B1 (en) * 1995-09-29 2001-08-14 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL329217A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Pain relieving method
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5929070A (en) * 1996-03-25 1999-07-27 Eli Lilly And Company Method for treating migraine pain with olanzapine
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
KR100516088B1 (ko) * 1996-09-23 2005-09-22 일라이 릴리 앤드 캄파니 올란자핀 이수화물 ｄ
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
EP1155696B1 (de) * 1997-04-15 2004-03-03 Eli Lilly And Company Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
TR200100885T2 (tr) * 1998-09-30 2001-08-21 Eli Lilly And Company 2-Metil-tieno-benzodiazepin formülasyonu
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
ES2240215T3 (es) * 1999-12-28 2005-10-16 Cipla Limited Nuevas formas polimorfas de olanzapina.
JP2004507548A (ja) * 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2003101997A1 (en) 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040229896A1 (en) * 2003-03-12 2004-11-18 Toth Zoltan G. Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005049090A2 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
PT1611139E (pt) * 2003-12-22 2008-07-17 Teva Pharma Métodos de preparação de olanzapina
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2006073886A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2006102176A2 (en) * 2005-03-21 2006-09-28 Dr. Reddy's Laboratories Ltd. Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (de) * 2005-08-17 2008-05-14 Synthon B.V. Verfahren zur herstellung von olanzapin form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP2888590B1 (de) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antikörper gegen olanzapin und verwendung davon
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
CN109400708A (zh) 2012-08-21 2019-03-01 詹森药业有限公司 奥氮平半抗原的抗体及其用途
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
PT582368E (pt) * 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
EG23659A (en) 2007-03-26
ATA902196A (de) 2000-01-15
ATE251627T1 (de) 2003-10-15
MY114701A (en) 2002-12-31
LV12018A (lv) 1998-04-20
LT4349B (lt) 1998-05-25
DE69630324T2 (de) 2004-07-29
PL322501A1 (en) 1998-02-02
EA199700262A1 (ru) 1998-02-26
IS1896B (is) 2003-10-20
KR100399688B1 (ko) 2004-02-18
GB2313835B (en) 1998-09-16
ATE204280T1 (de) 2001-09-15
NO314663B1 (no) 2003-04-28
CA2214005A1 (en) 1996-10-03
ES2208220T3 (es) 2004-06-16
DE69636313T2 (de) 2007-05-31
DK0733635T3 (da) 2001-10-08
IL117610A (en) 2001-08-26
LV12018B (en) 1998-09-20
EE03489B1 (et) 2001-08-15
YU17796A (sh) 1999-03-04
HK1013988A1 (en) 1999-09-17
DE69614426D1 (de) 2001-09-20
TW442488B (en) 2001-06-23
SI9620040A (sl) 1998-06-30
KR19980703188A (ko) 1998-10-15
GB2313835A (en) 1997-12-10
EP0733635A1 (de) 1996-09-25
CZ292688B6 (cs) 2003-11-12
SV1996000031A (es) 1998-03-27
PT733635E (pt) 2001-12-28
TR199701017T1 (xx) 1998-01-21
ZA962344B (en) 1997-09-22
ATE331719T1 (de) 2006-07-15
IS4564A (is) 1997-09-22
DK1445259T3 (da) 2006-10-16
AR002719A1 (es) 1998-04-29
PT1095941E (pt) 2004-02-27
RO118872B1 (ro) 2003-12-30
AU5427996A (en) 1996-10-16
HU224989B1 (en) 2006-05-29
SI0733635T1 (en) 2002-06-30
JPH11502535A (ja) 1999-03-02
CA2214005C (en) 2001-07-03
SE9703205L (sv) 1997-09-05
ES2266719T3 (es) 2007-03-01
CH690579A5 (de) 2000-10-31
EP1445259A1 (de) 2004-08-11
CN1065536C (zh) 2001-05-09
CO4650278A1 (es) 1998-09-03
NZ306110A (en) 1998-09-24
DK108997A (da) 1997-11-12
EP1445259B1 (de) 2006-06-28
US5736541A (en) 1998-04-07
DE19681286T1 (de) 1998-04-02
TW513432B (en) 2002-12-11
HUP9802824A2 (hu) 1999-06-28
DE69614426T2 (de) 2002-05-23
YU49478B (sh) 2006-05-25
FI973750A (fi) 1997-09-22
EP1095941A1 (de) 2001-05-02
PE44897A1 (es) 1997-10-22
BG101900A (en) 1999-03-31
LU90096B1 (fr) 1997-07-22
SK121897A3 (en) 1998-03-04
IL117610A0 (en) 1996-07-23
SI1095941T1 (en) 2003-12-31
MX9707183A (es) 1997-11-29
EA000149B1 (ru) 1998-10-29
NO974365L (no) 1997-09-22
ZA962342B (en) 1997-09-22
SE9703205D0 (sv) 1997-09-05
ES2159346T3 (es) 2001-10-01
GB9719819D0 (en) 1997-11-19
CN1179160A (zh) 1998-04-15
FI973750A0 (fi) 1997-09-22
AP828A (en) 2000-04-28
SI9620040B (sl) 2002-02-28
AU706471B2 (en) 1999-06-17
HUP9802824A3 (en) 2000-01-28
EP1095941B1 (de) 2003-10-08
BR9607790A (pt) 1998-07-07
SI1445259T1 (sl) 2006-10-31
DE69630324D1 (de) 2003-11-13
BG62619B1 (bg) 2000-03-31
DK1095941T3 (da) 2004-02-16
AT406771B (de) 2000-08-25
CZ300097A3 (en) 1997-12-17
PL183723B1 (pl) 2002-07-31
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
UA44765C2 (uk) 2002-03-15
EE9700232A (et) 1998-04-15
EP0733635B1 (de) 2001-08-16
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
OA10510A (en) 2002-04-24
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
SK284143B6 (sk) 2004-10-05
LT97148A (en) 1998-01-26

Similar Documents

Publication Publication Date Title
DE69636313D1 (de) Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE69634998D1 (de) Kontrolle von Kanten
DE69431880T2 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE69626729D1 (de) Kombination von Datenwerten
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
NL300284I2 (nl) Kristalmodificatie van
ATE172762T1 (de) Verwendung von ethylenaminen bei der lignin- entfernung
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE59610014D1 (de) Schwingquarzsensor
DE69827393D1 (de) Kosmetische verwendung von bis-resorcinol-triazinderivaten
DE69618264T2 (de) Verbesserungen bei der Herstellung von Kristallsubstraten
DE69612725D1 (de) Kristallhaltevorrichtung
DE59401861D1 (de) Verwendung von ferrocen
DE69605708D1 (de) Reinigung von Pentafluorethan
DE69606449D1 (de) Züchtung von Silizium-Einkristall
DE19681567T1 (de) Flüssigkristallzusammensetzung
DE69515021T2 (de) Ausrichtung von Interferometern
DE59308823D1 (de) Verwendung von Thioalkandionen als Aromastoffe
ATE210605T1 (de) Verwendung von sulfonamiden zur kontrolle von biobewuchs
DE69623886D1 (de) Entfernung von Spleissbändern
DE59501871D1 (de) Monocarbonsäureamide von Polyaminen
DE69508469T2 (de) Oxyde-Granat-Einkristall
KR960032349U (ko) 액정표시장치의 백라이트 구조
DE59507095D1 (de) Verwendung von detergensgemischen
KR970002716U (ko) 액정표시소자

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN